ARTICLE | Clinical News
AVI BioPharma starts Phase II with Resten-NG
June 28, 2000 7:00 AM UTC
AVII started a 120-patient U.S. Phase II trial of Resten-NG antisense compound to treat cardiovascular restenosis following angioplasty. Resten-NG was developed with AVII's NeuGene antisense technolog...